Takhzyro (lanadelumab) may be better than Cinryze at preventing swelling episodes in hereditary angioedema (HAE), according to a study based on data from Phase 3 clinical trials. The study, “Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study,” was published…
Treatment with tranexamic acid may ease symptoms and prevent intubation in people who develop angioedema after receiving certain high blood pressure medications called angiotensin-converting enzyme (ACE) inhibitors, a review of published studies shows. The findings also suggest tranexamic acid may be more advantageous than other therapies currently used to…
The U.S. Food and Drug Administration (FDA) has given STAR-0215 fast track status to help speed up its development and make it available to patients sooner. An experimental medication to prevent swelling attacks in hereditary angioedema (HAE), with dosing once every three or six months, STAR-0215 is in…
Pharvaris’ PHVS416, a soft-gel capsule of PHA121, now also known as deucrictibant, continues to show promising safety and effectiveness for treating swelling attacks in people with hereditary angioedema (HAE). That’s according to data from RAPIDe-1 (NCT04618211), a Phase 2 clinical trial that’s comparing on-demand treatment with PHVS416…
People with hereditary angioedema (HAE) who took Orladeyo (berotralstat) for up to two years experienced no swelling attacks for most of the treatment duration, with fewer swelling attacks translating into a better quality of life. That’s according to results from APeX-S and APeX-2, two clinical studies that evaluated…
A single dose of Berinert, a concentrate of C1 esterase inhibitor, when given with standard treatment, may not do more to ease angioedema airway symptoms triggered by a type of medication called an angiotensin-converting enzyme (ACE) inhibitor, a study found. The study, “Efficacy of human C1 esterase…
Donidalorsen, a small molecule therapy being developed by Ionis Pharmaceuticals, continues to be safe and to prevent swelling attacks when taken for up to one year by people with hereditary angioedema (HAE), trial data show. The open-label extension study (NCT04307381) is ongoing in patients who completed a placebo-controlled…
Astria Therapeutics has launched a Phase 1a trial in healthy adults to test STAR-0215, an investigational antibody-based therapy designed to prevent swelling attacks in people with hereditary angioedema (HAE), with dosing once every three months or longer. The launch came soon after the U.S. Food and Drug Administration…
The U.S. Food and Drug Administration (FDA) has cleared Astria Therapeutics to move STAR-0215, its experimental treatment for preventing swelling attacks in hereditary angioedema (HAE), into clinical testing. With the positive decision on its investigational new drug (IND) application, the company is now planning to launch a Phase…
Dermatologists, pediatricians, and emergency doctors may be more aware of hereditary angioedema (HAE) than doctors of other specialties, according to an online survey conducted in Japan. This discrepancy among healthcare professionals highlights the importance of educational efforts and specialist accreditation in raising awareness about the condition within the medical…
Get regular updates to your inbox.